Renalytix Plc
RENXF
$0.091
-$0.039-30.00%
| 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | 09/30/2023 | |
|---|---|---|---|---|---|
| Revenue | -18.70% | -32.74% | -40.23% | -36.65% | -16.31% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -18.70% | -32.74% | -40.23% | -36.65% | -16.31% |
| Cost of Revenue | -17.52% | -20.50% | -16.51% | -18.89% | -2.96% |
| Gross Profit | -25.99% | -78.33% | -103.45% | -85.10% | -54.71% |
| SG&A Expenses | -35.46% | -30.76% | -33.82% | -31.55% | -33.41% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -37.48% | -31.70% | -27.56% | -23.27% | -25.30% |
| Operating Income | 38.86% | 31.62% | 26.52% | 22.23% | 25.89% |
| Income Before Tax | 36.03% | 26.65% | 5.44% | 0.90% | 6.99% |
| Income Tax Expenses | 100.00% | 100.00% | -65.22% | -70.83% | -87.50% |
| Earnings from Continuing Operations | 36.02% | 26.64% | 5.47% | 0.94% | 7.03% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 36.02% | 26.64% | 5.47% | 0.94% | 7.03% |
| EBIT | 38.86% | 31.62% | 26.52% | 22.23% | 25.89% |
| EBITDA | 38.93% | 31.83% | 26.55% | 22.42% | 25.12% |
| EPS Basic | 48.20% | 41.93% | 23.10% | 20.54% | 21.35% |
| Normalized Basic EPS | 50.26% | 44.11% | 31.20% | 23.61% | 24.24% |
| EPS Diluted | 47.86% | 40.84% | 28.40% | 25.61% | 26.12% |
| Normalized Diluted EPS | 50.26% | 44.11% | 31.20% | 23.61% | 24.24% |
| Average Basic Shares Outstanding | 25.74% | 30.05% | 23.74% | 25.19% | 18.69% |
| Average Diluted Shares Outstanding | 25.74% | 30.05% | 23.74% | 25.19% | 18.69% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
